Curriculum Vitae of
`Dr. Uday Kompella
`
`
`
`Metrics EX1052, Page 1
`
`

`
`CURRICULUM VITAE.
`
`Uday B. Kompella, Ph.D.
`Professor
`Department of Pharmaceutical Sciences
`University of Colorado Denver
`12700 East 19th Avenue, C-238-P15
`Aurora, CO 80045
`Phone: (303) 724-4028; E-mail: Uday.Kompella@ucdenver.edu
`
`
`
`PERSONAL DATA
`
`Home Address:
`
`Citizenship:
`
`EDUCATION
`
`
`
`
`Years Attended
`
`11614 East Lake Place, Englewood, CO 80111
`
`USA
`
`Degree
`
`Institution and Location
`
`08/1989-03/1994
`
`PhD (Pharm. Sci.)
`
`08/1987-02/1989
`
`M.Pharm (Pharm. Engg.)
`
`08/1983-07/1987
`
`B.Pharm (Hons)
`
`University of Southern
`California, Los Angeles
`
`Jadavpur University, Calcutta,
`India
`
`Birla Institute of Technology
`and Science, Pilani, India
`
`
`ACADEMIC APPOINTMENTS
`
`03/11-present Professor, Department of Bioengineering (courtesy), University of Colorado
`Denver, Aurora, CO 80045.
`
`
`03/08-
`
`Professor, Department of Pharmaceutical Sciences (primary) and Department of
`Ophthalmology (courtesy), University of Colorado Denver, Aurora, CO 80045
`(tenured).
`
`
`07/01 – 03/08 Associate Professor, Department of Pharmaceutical Sciences, UNMC College of
`Pharmacy, Omaha, Nebraska (tenured)
`
`
`07/02 – 03/08 Associate Professor, Department of Ophthalmology, UNMC, Omaha, NE
`(Courtesy faculty appointment)
`
`
`07/00 – 06/02 Assistant Professor, Department of Ophthalmology, UNMC, Omaha, NE
`(Courtesy faculty appointment)
`
`
`
`
`Key Areas of Interest: Ocular and respiratory drug delivery & disposition; Nanotechnology for
`drug delivery; Supercritical fluid technology for drug delivery systems; Antiangiogenic drugs for
`the therapy of diabetic retinopathy, age related macular degeneration, and cancers.
`
`
`
`
`1
`
`Metrics EX1052, Page 2
`
`

`
`07/98-06/01
`
`09/94-06/98
`
`Assistant Professor, Department of Pharmaceutical Sciences, UNMC College of
`Pharmacy, Omaha, Nebraska
`
`
`Assistant Professor, Department of Pharmacal Sciences, School of Pharmacy,
`Auburn University, Auburn, Alabama
`
`
`
`Registered Pharmacist, State of Andhra Pradesh, India
`
`Chair, Pharmaceutical Sciences Graduate Program, UNMC, Omaha, NE
`
`CERTIFICATIONS AND LICENSES
`
`1987
`
`OTHER APPOINTMENTS
`
`12/08-present Member, Diabetes & Endocrinology Research Center (DERC), UCD, CO
`
`12/08-present Member, Cancer Center, UCD, CO
`
`03/08-present Member, Center for Pharmaceutical Biotechnology
`
`07/05-07/07
`
`07/05-03/08 Member, Center for Drug Delivery and Nanomedicine, UNMC, Omaha, NE
`
`07/04-03/08 Member, Biomedical Engineering Research Initiative & Graduate Program,
`University of Nebraska System
`
`
`09/98-present Graduate Faculty Member and Graduate Faculty Fellow, UNMC, Omaha, NE
`
`09/98-03/08
`
`04/94-08/94
`
`08/90-12/93
`
`08/89-07/90
`
`Associate Member, Cancer Center, UNMC, Omaha, NE
`
`Research Scientist, Balance Pharmaceuticals, Inc., Los Angeles, California
`
`Research Assistant, University of Southern California, Los Angeles, CA
`
`Teaching Assistant, University of Southern California, Los Angeles, CA
`
`03/89-07/89 Medical Representative, Merind Limited, Bombay, India
`
`
`
`SCIENTIFIC ADVISORY BOARDS
`
`
`2009-
`
`2009-
`2008-2010
`2008-
`
`2008-
`
`
`Combination Products Advisory Committee, Vistakon (A Johnson & Johnson Co.)
`The Glaucoma Foundation
`Visionary Therapeutics Corporation
`Appian Laboratories
`PCAsso Diagnostics
`
`
`
`HONORS AND AWARDS
`
`2013
`
`
`
`Selected to receive Gold Fellow Status, American Association for Research in
`Vision and Ophthalmology
`
` Outstanding Achievement Award, American Association of Pharmaceutical
`Scientists
`
`2
`
`
`2013
`
`
`
`
`
`Metrics EX1052, Page 3
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2012
`
`
`2012
`
`
`2012
`
`2012
`
`
`2011
`
`
`2011
`
`
`2010
`
`
`2009
`
`
`2008
`
`2008
`
`
`2006
`
`
`2005
`
`
`2005
`
`
`2003
`
`
`2002
`
`
`1997-98
`
`1997
`
`
`1997
`
`1996
`
`
`
`
`
`Dean’s Mentoring Award In Recognition of Exemplary Thesis Advising. Anschutz
`Medical Campus, University of Colorado.
`
`ARVO/AFER/Pfizer/Carl Camras
`Ophthalmology.
`
`Translational Research
`
`Award
`
`in
`
`Distinguished scientist seminar at Medical College of Georgia, Augusta, GA.
`
`Visiting Professor, University of Kentucky Department of Ophthalmology, October
`26, 2012.
`
`1st Annabil Musick Gardner Convocation Lecturer, University of Colorado Denver,
`Aurora, CO.
`
`Keynote Lecture at Thadikonda Pharmaceutical Sciences Symposium. LV
`Prasad Eye Institute (LVPEI), Hyderabad, India.
`
`FARVO Designation, Silver Fellow, Association for Research in Vision and
`Ophthalmology.
`
`Key Note Lecture, ASIA-ARVO, Association for Research in Vision and
`Ophthalmology, Hyderabad, India.
`
`Service Award, Regulatory Sciences Section, AAPS
`
`Resaearch Innovation Award for Licensed Technology. University of Nebraska
`Medical Center. Functionalized particles to treat eye disorders.
`
`Distinguished Scientist, University of Nebraska Medical Center. In recognition of
`leading an outstanding research program at the University.
`
`Fellow, American Association of Pharmaceutical Scientists. Recognition “as a
`distinguished contributor and acknowledged leader in the advancement of
`pharmaceutical sciences”.
`
`Recognition Award, Regulatory Sciences Section, American Association of
`Pharmaceutical Scientists
`
`Distinguished Teaching Award, University of Nebraska Medical Center, Omaha,
`NE.
`
`Award of Appreciation by Graduate Students - In recognition of contributions and
`support as a faculty advisor. XXXIV Annual Pharmaceutics Graduate Research
`Meeting (June 13-15, 2002). Department of Pharmaceutical Sciences, University
`of Nebraska Medical Center, Omaha, NE.
`
`Alumni Undergraduate Teaching Excellence Award, Auburn University
`
`Recipient of AAPS new investigator grant in pharmaceutics, drug delivery and
`pharmaceutical technology for 1997. Sponsored by Pfizer Central Research
`
`
`
`Recognition Award. American Association of Indian Pharmaceutical Scientists
`
`Who’s Who in Science and Engineering, The Marquis Who’s Who Publication
`Board.
`
`3
`
`Metrics EX1052, Page 4
`
`

`
`Full member, Sigma Xi, The Scientific Research Society
`
`Outstanding Achievement, Office of
`Southern California, Los Angeles, CA
`
`International Students, University of
`
`Student Assistantship from Genentech, Inc. to attend Western Regional AAPS
`meeting held at San Francisco, CA
`
`Outstanding paper in pharmacokinetics, pharmacodynamics, drug metabolism,
`and clinical sciences (PPDM & CS) section of AAPS meeting held at San
`Antonio, sponsored by Eli Lilly & Co.
`
`Best poster award in the graduate student research forum (GSRF) at University
`of Southern California, sponsored by Doheney Eye Institute, Los Angeles, CA.
`
`Fellowship from University Grants Commission, New Delhi, India
`
`National Merit Scholarship, India
`
`1995
`
`1994
`
`
`1993
`
`
`1992
`
`
`1992
`
`
`1987-89
`
`1983-87
`
`
`
`EDITORSHIPS AND EDITORIAL BOARD MEMBERSHIPS
`
`2011-present Editor-in-Chief, Expert Opinion on Drug Delivery
`
`2011-present Associate Editor, Journal of Ocular Pharmacology and Therapeutics
`
`2008-present Field Editor, Research manuscripts in the area of nanotechnology for drug
`delivery, gene delivery, and imaging. Pharmaceutical Research
`
`
`2004-2008
`
`journal
`Editor, Expert Reviews, Pharmaceutical Research, A Springer
`(responsibilities include a) managing the article invitations, peer reviews, and
`decision making on acceptability of articles; and b) developing and implementing
`strategic plans to enhance the journals impact by identifying key areas of future
`focus and by recruiting high impact manuscripts and authors)
`
`
`2004-12/2008 Editor, Clinical Research and Regulatory Affairs, A Taylor & Francis journal
`(responsibilities include a) managing the article invitations, peer reviews, and
`decision making on acceptability of articles; and b) developing and implementing
`strategic plans to sustain and nurture research activity in the areas of drug,
`device, and biologics development and to enhance the journals visibility; I am
`one of the two editors of the journal; there is no editor-in-chief for this journal
`above the editors)
`
`
`2007-present Member, Editorial Board, Journal of Ocular Pharmacology and Therapeutics
`(Associate Editor Responsibilities)
`
`
`2007-present Member, Editorial Advisory Board, Journal of Ocular Biology, Diseases, and
`Informatics
`
`
`2007-present Member, Editorial Advisory Board, International Journal of Pharmaceutical
`Sciences and Nanotechnology
`
`
`2004-present Member, Editorial Advisory Board, Expert Opinion on Drug Delivery
`
`2003-present Member, Editorial Board, Focus, Newsletter of Ocular Drug Delivery &
`Disposition Focus Group, American Association of Pharmaceutical Scientists
`
`
`
`4
`
`Metrics EX1052, Page 5
`
`

`
`
`2001-present Member, Editorial Advisory Board, Drug Delivery Technology
`
`2001
`
`Guest Member, Editorial Advisory Board, Investigative Ophthalomology and
`Visual Science
`
`
`MEMBERSHIPS AND OFFICES IN PROFESSIONAL ASSOCIATIONS
`
`Membership
`
`2008-present Member, American Society for Pharmacology and Experimental Therapeutics
`
`2006-present Member, American Association for the Advancement of Science
`
`2004-present Member, International Society for Eye Research
`
`1998-present Controlled Release Society
`
`2001-
`
`1995-99
`
`1994-
`
`1990-present American Association of Pharmaceutical Scientists
`
`1990-present Association for Research in Vision and Ophthalmology
`
`Elected Offices
`
`1. Nanotechnology and Regenerative Medicine Cross-sectional Group, Annual Meeting
`Program Committee, Association for Research in Vision and Ophthalmology. 2013-2018.
`
`2. Physiology and Pharmacology Section Representative, Annual Meeting Program Committee,
`Association for Research in Vision and Ophthalmology. 2009-2012.
`
`
`
`
`
`American Diabetes Association
`
`Sigma Xi, The Scientific Research Society
`
`American Association of Colleges of Pharmacy
`
`
`3. Chair, Regulatory Sciences Section, American Association of Pharmaceutical Scientists,
`2003-2004.
`
`
`2. Chair-Elect, Regulatory Sciences Section, American Association of Pharmaceutical
`Scientists, 2002-03.
`
`
`3. Chair, Ocular Drug Delivery and Disposition Focus Group, American Association of
`Pharmaceutical Scientists. 2001-2003.
`
`
`4. Vice Chair, Regulatory Sciences Section, American Association of Pharmaceutical Scientists,
`2001-02.
`
`
`5. Secretary, Ocular Drug Delivery and Disposition Focus Group, American Association of
`Pharmaceutical Scientists. 1999-2001.
`
`
`6. Secretary/Treasurer, Regulatory Affairs Section, American Association of Pharmaceutical
`Scientists. 1998-01.
`
`
`GRANT/CONTRACT SUPPORT
`
`
`
`
`5
`
`Metrics EX1052, Page 6
`
`

`
`Grants Funded (Role: principal investigator; Direct costs are indicated unless otherwise stated;
`indirect costs charged at UCD, UNMC, and Auburn University for federally funded grants
`are 54, 47, and 44% respectively. Indirect costs for industry projects are 28, 26, and 44%
`at UCD, UNMC, and Auburn University, respectively).
`
`
`1.
`
`In vitro-in vivo correlation of ocular implants. FDA U01FD004929 grant. ~$565,000.
`09/15/2013-09/14/2014. Role: PI.
`
`2. Suprachoroidal drug delivery for retinal disorders. NIH R01EY022097 Grant. Total costs:
`~2,700,000 09/30/2013-09/29//2017. Role: MPI with Mark Prausnitz (Georgia Tech).
`
`3. Ocular diffusion and partitioning studies. Alcon Research Limited. ~120,000. 09/2013-
`08/2013. Role: PI.
`
`4. Transscleral therapeutics for diabetic retinopathy. NIH R01EY018940 Grant. Total costs:
`~$2,200,000. 04/01/2010-03/31/2015. Role: PI.
`
`5. Supplement (equipment) to translational therapeutics in diabetic retinopathy. NIH R01 S1
`grant. $499,000. 09/01/2012-08/31/2013. Role: PI.
`
`6. Effect of physicochemical properties of ophthalmic formulations on ocular bioavailability. FDA
`U01FD004719 grant. $494,634. 09/12/2012-09/11/2013. Role: PI. No cost extension for
`2013.
`
`7. Novel lung cancer therapeutics. Cancer League of Colorado. $30,000. 06/01/2012-
`05/31/2013. Role: PI.
`
`8. Novel protein drug for wet age releated macular degeneration (AMD). Colorado BDEGP
`Grant. $196,560. 3/21/2012-9/30/2013. Role: PI.
`
`9. DERC pilot and feasibility study. Targeted nanoparticles. DERC, UCD. Total costs: $40,000,
`04/11-03/12. Role: PI at 2% effort.
`
`10. Drug delivery to the back of the eye: From bench to bedside. NIH R13 grant. $33,880.
`09/01/2011-08/31/2012. Role: PI.
`
`11. Novel Tools and Themes in Vision Sciences. Indo-US Science and Technology Forum grant.
`$25,000. 07/2012-06/2012. Role: US PI. Budget is for speaker expense reimbursement by
`the Indian government.
`
`12. Topical nanoparticles for CNV. NIH STTR Grant. Total costs: $271,468. 09/01/2010-
`08/31/2011. Role: PI.
`
`
`13. Development of small heat shock proteins as therapeutic agents in the eye. NIH RC1 Grant.
`Total costs: $992,278. 09/30/09-08/31/11. Role: Co-PI at 20% effort. About 50% of the
`budget was allocated for Dr. Kompella.
`
`14. Influence of eye pigmentation and diabetes on retinal drug delivery. NIH R01 Grant. Total
`costs: $805,866. 09/01-09-08/31/11. Role: PI at 25% effort.
`
`
`15. In vivo pharmacokinetic evaluation of dorzolamide and brinzolamide. Merck & Co., Inc. Total
`costs: $90,000. 01/01/2010-12/31/2010. Role: PI.
`
`16. Delivery of SAR 1118 to the eye and its efficacy in a diabetic rat model. Sarcode. Direct
`costs: $253,400. 7/15/08-7/14/10. Role: PI at 10% effort.
`
`
`
`
`
`6
`
`Metrics EX1052, Page 7
`
`

`
`17. Microparticle formulations for sustained delivery of TG-0054. TaiGen Biotechnology. Direct
`costs: $140,307. 07/01/08-06/30/09. Role: PI at 5% effort.
`
`
`18. In vivo pharmacokinetic evaluation of gatifloxacin-g6 dendrimer complex. Visionary
`Therapeutics Co. Direct costs: $59,524. 08/01/09-10/31/09. Role: PI at 5% effort.
`
`
`19. DPT dendrimers for topical administration. Visionary Therapeutics Co. Direct costs:
`$154,500. 08/01/08-02/28/09. Role: PI at 10% effort.
`
`
`20. Delivery of LEDGF for Retinal Degenerative Disorders. R21 Grant. Total costs: $392,500.
`04/01/2007-03/31/2009. NIH priority score: 120. Role: PI at 25% effort.
`
`
`21. Transscleral drug delivery for retinal disorders. R24 Grant for Collaborative Vision Research.
`Collaborative grant between Emory University, Georgia Tech, University of Nebraska, and
`University of Pennsylvania. $1,234,800 total costs to Dr. Kompella at UNMC – i.e.,
`246,960/yr. 07/01/06-06/30/11. Role: PI on UNMC component at 30% effort (PI of the
`multiuniversity, multi-million dollar project: Henry Edelhauser, Emory University).
`
`
`22. Development of a model for back of the eye drug delivery. Pfizer Global Research and
`Development, Groton, CT. $100,000. 01/07-12/07. Role: PI.
`
`
`23. Corticosteroid delivery and myocilin expression. Allergan, Inc., Irvine, CA. $78, 027. 01/07-
`12/07. Role: PI.
`
`
`24. Unrestricted gift for ocular drug delivery research. Pfizer Global Research and Development,
`Groton, CT. $25,000. 11/06-present. Role: PI.
`
`
`25. Subretinal fluorophore injection – Solute disposition feasibility study. Surmodics, Inc., Irvine,
`CA. $64,676 (total). 06/01/06-05/31/07. Role: PI.
`
`
`26. Pharmacological approaches to treat diabetic retinopathy – minority supplement (R01
`DK064172-S1). National Institutes of Health, Bethesda, MD. 04/03-03/06. Role: PI-30%.
`
`
`27. Pharmacological approaches to treat diabetic retinopathy (R01 DK064172). National
`Institutes of Health, Bethesda, MD. Total costs: $704,130. 04/03-03/07. Role: PI-30%.
`
`
`28. Subconjunctival route to prolong corticosteroid delivery (R03 EY013842). National Institutes
`of Health (NEI), Bethesda, MD. Total costs: $441,000, 08/01/03-07/31/07. Role: PI-20%.
`
`
`29. Corneal and scleral permeability of drugs. Ophtha Technical Development, Novartis AG,
`Basel. $59,000 (total), 01/05-12/05. Role: PI.
`
`
`30. Anti-VEGF and antiproliferative effects of AQ4N, a bioreductive drug. Novacea, Inc., $64,000
`(total), 07/01/04-06/30/05. Role: PI
`
`
`31. Biocompatibility of SABER formulations in the eye. Durect Corporation. $37,000 (total),
`07/01/04-06/30/05. Role: PI-3%
`
`
`32. Equipment for supercritical fluid processes. Nebraska Banker’s Association. $15,000. June
`2004. Role: PI.
`
`
`33. Ocular drug disposition from novel Alcon formulations. Alcon Research, Ltd., Fort Worth, TX.
`$63,256. 12/11/2003-12/11/2003.
`
`
`34. Ocular drug delivery research. Santen Corporation, Japan, $20,000. 2002-prsent.
`Unrestricted funding.
`
`
`
`7
`
`Metrics EX1052, Page 8
`
`

`
`
`35. Retinal delivery of celecoxib to inhibit VEGF expression. UNMC seed grant, $24,550, 2001.
`
`36. Fluocinolone as an inhibitor of VEGF expression and angiogenesis. Controlled Delivery
`Systems, Inc., Watertown, MA. $20,425, 04/01/2001-01/14/02.
`
`
`37. Deslorelin transport across bovine nasal tissue. Balance Pharmaceuticals, Inc., Santa
`Monica, CA. $16,000, 12/01/00 – 11/30/02.
`
`
`38. Assessment of bovine nasal tissue for peptide drug transport: A feasibility study with
`deslorelin. Balance Pharmaceuticals, Inc., Santa Monica, CA. $4,157, 08/01/00 - 07/31/01.
`(Role: PI).
`
`
`39. Mechanisms and kinetics of degradation of deslorelin in nasal epithelial cells. Balance
`Pharmaceuticals, Inc., Santa Monica, CA. $36,456, 03/01/00 - 02/28/01. (Role: PI).
`
`
`40. Ocular absorption of levobetaxolol from novel formulations - 1. Alcon Laboratories, Inc., Fort
`Worth, TX. $36,655, 10/98-10/00 (Role: PI).
`
`
`41. AAPS new investigator grant in pharmaceutics, drug delivery and pharmaceutical technology.
`Unrestricted research funding. $10,000, 08/98-07/00. (Role: PI).
`
`
`42. Ocular absorption of levobetaxolol. Alcon Laboratories, Inc., Fort Worth, TX. $14,120, 08/98-
`indefinite. (Role: PI).
`
`
`43. Systemic and ocular absorption of novel ARIs (R15 EY1177-03). National Institutes of Health
`(NEI), Bethesda, MD. $74,893, 03/01/97 - 02/29/00. Transferred $17,919 to UNMC during
`year 2; Carry over of $15,066 from year 1 was also transferred to UNMC. Direct costs
`received for year 3 are $24,790. (Role: PI; Co-investigators: Jack DeRuiter and C. Randall
`Clark).
`
`
`44. Production of budesonide particles for pulmonary delivery using supercritical fluid antisolvent
`precipitation technique. Auburn University Biogrant Proposal, Auburn University, Auburn, AL
`36849. $55,000, 12/97-11/99. (Role: PI; Co-investigator. Christopher B. Roberts, Department
`of Chemical Engineering).
`
`
`45. Ocular absorption of drugs from Alcon formulations. Alcon Laboratories, Inc., Fort Worth, TX.
`$7,000, 7/97-06/98 (Role: PI).
`
`
`46. A preliminary bioequivalence study of phenylbutazone paste in horses. Med-Pharmex, Inc.,
`Pomona, CA. $5,500, 4/97-8/97. (Role: PI. Co-investigators: William R. Ravis, Ram Purohit,
`Sue H. Duran).
`
`
`47. Mechanisms of transport of dideoxyinosine across cornea and conjunctiva. Future Life
`Science Scholars Program. Sponsored by Howard Hughes Institute through a core grant to
`Auburn University. $1,400, 6/97-9/97. (Role: Mentor for James Kelly, a high school student
`from Opelika).
`
`
`48. A sustained release device for deslorelin in treating cystic ovarian disease in cattle. Future
`Life Science Scholars Program. Sponsored by Howard Hughes Institute through a core grant
`to Auburn University. $1,000, 6/97-9/97. (Role: Mentor for Sharon Williams, a student from
`Tuskegee University).
`
`
`49. Fabrication and characterization of porous biodegradable membranes. DPD Inc., 2000
`Turner St., Lansing, MI 48906. $4,000, 8/96-10/96. (Role: PI).
`
`
`
`
`
`8
`
`Metrics EX1052, Page 9
`
`

`
`50. Fabrication and characterization of porous biodegradable membranes. Future Life Science
`Scholars Program. Sponsored by Howard Hughes Institute through a core grant to Auburn
`University. $1,000, 6/96-9/96. (Role: Mentor for a college student).
`
`
`51. ELISA analysis of deslorelin in rabbit plasma samples. Balance Pharmaceuticals, Inc., 842
`Las Casas Ave., Pacific Palisades, CA 90272. $2,000, 10/95-12/95. (Role: PI).
`
`
`52. Ocular Absorption Of Drugs From Ten Formulations; Alcon Laboratories, Inc., 6201 South
`Freeway, Fort Worth, TX 76134. $11,789, 8/95-7/97. (Role: PI).
`
`
`53. Influence of an anti-glaucoma agent on rabbit corneal and conjunctival ion transport; Sigma
`Xi Headquarters, 99 Alexander Drive- Box 13975, Research Triangle Park, NC 27709.
`$1,428, 3/95-2/96. (Role: PI).
`
`
`54. Deslorelin: HPLC assay and nasal degradation; Lab supplies for a high school student
`(Megan Huff) during summer; Future Life Science Scholars Program at Auburn Universtiy;
`Sponsored by Howard Hughes Institute. $1,800, 6/95-8/95. (Role: PI).
`
`
`55. Development and characterization of an in vitro model for drug and ion transport across
`rabbit nasal epithelial tissue. Auburn University Research Grant-in-Aid. $10,000, 5/1/95-
`4/30/96. (Role: PI).
`
`
`56. RIA and ELISA analysis of estradiol, testosterone, and deslorelin in human serum samples.
`Balance Pharmaceuticals, Inc., 842 Las Casas Ave., Pacific Palisades, CA 90272. $1,847,
`3/95. (Role: PI).
`
`
`57. RIA and ELISA analysis of estradiol, testosterone, and deslorelin in rabbit plasma samples.
`Balance Pharmaceuticals, Inc., 842 Las Casas Ave., Pacific Palisades, CA 90272. $3,680,
`3/95. (Role: PI).
`
`
`58. RIA and ELISA analysis of estradiol, testosterone, and deslorelin in rabbit plasma samples.
`Balance Pharmaceuticals, Inc., 842 Las Casas Ave., Pacific Palisades, CA 90272. $4,489,
`2/95. (Role: PI).
`
`
`Grants Funded (Role: Co-investigator)
`
`59. Effective therapies for ocular injuries by vesicating agents. NIH U01EY023143. Total costs:
`$3,750,000. 09/01/2012-08/31/2017. Role: Co-I at 3% (PI: Rajesh Agarwal, University of
`Colorado Denver).
`
`60. HuR targeted nanotherapy for lung cancer. NIH R01CA167516. Total costs: ~2,000,000;
`~$40,000 direct costs/yr to U Colorado. 01/01/2013-12/31/2017. Role: Co-I at 3% (PI:
`Ramesh Rajagopal, University of Oklahoma Health Sciences Center).
`
`61. Preparation of slow release delivery systems for plasma kallikrein inhibitors. Subcontract on
`JDRF grant entitled “Validation of plasma kallikrein as a therapeutic target for diabetic
`complications” to Dr. Edward Feener at Harvard University. $72,980. 08/01/2012-07/31/2013.
`Role: PI on subcontract at 5% effort.
`
`62. Intraceptor interference of VEGF pathways. NIH R01 Grant. Total costs for Dr. Kompella’s
`part: $115,500. 04/07-03/12. Role: Co-I at 4% (PI: Bala Ambati, Medical College of Georgia,
`Augusta, GA).
`
`
`63. Pre-mRNA interference of VEGF pathways in ocular angiogenesis. Veterabs Affairs Merit
`Award. $150,000 (Dr. Kompella’s part; direct costs; no indirect costs allowed), 09/30/09-
`09/30/12. Role: Co-I at 5% effort.
`
`
`
`9
`
`Metrics EX1052, Page 10
`
`

`
`
`64. Genetic predictors of thiazolidinedione response. NIH K23K23DK073197. 08/09-06/11. Role:
`Co-I at 4% (PI: Dr. Christina Aquilante, University of Colorado Denver).
`
`65. The role of P-glycoprotein in sitagliptin clinical pharmacology. NIH R03DK084089. 08/24/09-
`06/30/11. Role: Co-I at 2% (PI: Christina Aquilante, University of Colorado Denver).
`
`
`66. A novel highly adaptable and multifunctional PEGylated dendrimer hydrogel platform for
`ocular drug delivery. Coulter translational research award in biomedical engineering. Phase I.
`Wallace H. Coulter Foundation, Miami, FL. Subcontract through Virginia Commonwealth
`University. Direct costs: $78,333. Total costs: $94,000. 9/1/09 – 8/31/11.Role: Co-I at 8%
`effort.
`
`
`67. Stem cell approach to AMD. Lincy Foundation. $994,000 (direct costs). 01/07-12/10. Role:
`Co-I at 10% (PI: Iqbal Ahmed, UNMC).
`
`
`68. Pharmacokinetics of nonsteroidal anti-inflammatory drugs in South American Camelids.
`Morris Animal Foundation, 45 Inverness Drive East, Englewood, CO 80112; $11,100, 11/97-
`10/98. (Role: Co-investigator; PI: Christine Navarre).
`
`
`69. Assessment of self-learning ability: Validation of scales and outcome measures. Auburn
`University Research Grant-in-Aid proposal. $2.040. 10/97. (PI: Debbie C. Byrd; Co-
`investigators: Uday B. Kompella and E. Chuma Wadibia).
`
`
`70. Novel GnRH agonist therapy for cystic ovaries in cattle. USDA for Food Animal Health and
`Disease Research, College of Veterinary Medicine, Auburn University, Auburn, AL 36830;
`$7,000, 10/97-9/98. (Role: Co-Investigator; PI: James G.W. Wenzel, College of Veterinary
`Medicine, Auburn University).
`
`
`71. Corneal and conjunctival transport of novel aldose-reductase inhibitors. Future Life Science
`Scholars Program. Sponsored by Howard Hughes Institute through a core grant to Auburn
`University. $1,400, 6/97-9/97. [Role: Co-advised (along with Jack DeRuiter) Erika Thomas, a
`high school student from Mississippi].
`
`
`72. A novel LHRH agonist therapy for cystic ovaries in cattle. USDA for Food Animal Health and
`Disease Research, College of Veterinary Medicine, Auburn University, Auburn, AL 36830.
`$18,000, 10/96-9/97. (Role: Co-investigator; PI: James Wenzel, College of Veterinary
`Medicine, Auburn University).
`
`
`73. Development of a nasally administered vaccine to combat Pasteurella haemolytica in cattle.
`USDA for Food Animal Health and Disease Research, College of Veterinary Medicine,
`Auburn University, Auburn, AL 36830. $20,000, 10/96-9/97. (Role: Co-investigator; PI: Sue
`Hudson Duran, College of Veterinary Medicine, Auburn University).
`
`
`74. Regional administration of ceftiofur for the treatment of septic foot conditions in cattle. USDA
`for Food Animal Health and Disease Research, College of Veterinary Medicine, Auburn
`University, Auburn, AL 36830. $16,500, 10/95-9/96. (Role: Co-investigator; PI: Christine B.
`Navarre, College of Veterinary Medicine, Auburn University).
`
`
`75. Development of a nasally administered vaccine to combat Pasteurella haemolytica in cattle.
`USDA for Food Animal Health and Disease Research, College of Veterinary Medicine,
`Auburn University, Auburn, AL 36830. $9,600, 10/95-9/96. (Role: Co-investigator; PI: Sue
`Hudson Duran, College of Veterinary Medicine, Auburn University).
`
`10
`
`
`
`
`
`Metrics EX1052, Page 11
`
`

`
`Competitive Funding Received for Graduate Student Research
`
`76. Fellowship award for the graduate research training of Gangadhar Sunkara, UNMC. $43,500
`(1999-2002).
`
`
`77. Fellowship award for the graduate research training of Jithan V. Aukunuru, UNMC. $29,000
`(2000-2002).
`
`
`78. Fellowship award for the graduate research training of Nagesh Bandi, UNMC. $36,000 (2001-
`2003).
`
`
`79. Fellowship award for the graduate research training of Kavitha Koushik, UNMC. $53,500
`(2000-2003).
`
`
`80. Fellowship award for the graduate research training of Surya P. Ayalasomayajula, UNMC.
`$69,500 (2000-2004).
`
`
`81. Fellowship towards the graduate research training of Narayan Cheruvu, UNMC. $58,000
`(2002-2005).
`
`
`82. Fellowship towards the graduate research training of Aniruddha Amrite, UNMC. $60,000
`(2003-2006).
`
`
`83. Fellowship towards the graduate research training of Devender Dhanda, American Heart
`Association. $55,000 (2004-2006).
`
`
`84. Fellowship towards the graduate research training of Swita Raghava, UNMC. $40,000 (2004-
`2006).
`
`
`85. Fellowship towards the graduate research training of Ashish Thakur, UNMC. $60,000 (2007-
`2010).
`
`
`86. Fellowship towards the graduate research training of Sneha Sundaram, American Heart
`Association. $55,000 (2007-2009).
`
`
`87. Fellowship towards the graduate research training of Shelley Durazo, NIH Biotechnology
`training grant. Fall 2010; Fall 2011; Spring 2011.
`
`11
`
`
`
`
`
`Metrics EX1052, Page 12
`
`

`
`PUBLICATIONS
`
`Journal/Scientific Magazine Articles: *Next to Dr. Kompella’s name indicates that he was the
`corresponding author.
`
`
`Kulkarni, S.S. and Kompella, U.B.* Potential drug delivery approaches for XFS and XFS
`associated glaucoma J. Glaucoma (submitted).
`
`Upadhyay, A.K. Petrash, J.M., Kompella, U.B.* Alpha crystalline nanoassemblies. ACS
`Nano (submitted).
`
`Rowe-Rendleman CL, Durazo SA, Kompella UB, Rittenhouse KD, Di Polo A, Weiner AL,
`Grossniklaus HE, Naash MI, Lewin AS, Horsager A, Edelhauser HF. Drug and gene
`delivery to the back of the eye: from bench to bedside. Invest Ophthalmol Vis Sci. 2014
`Apr 28;55(4):2714-30. doi: 10.1167/iovs.13-13707. Review. PubMed PMID: 24777644;
`PubMed Central PMCID: PMC4004426.
`
`Rajashekhar G, Shivanna M, Kompella UB, Wang Y, Srinivas SP. Role of MMP-9 in the
`breakdown of barrier integrity of the corneal endothelium in response to TNF-α. Exp Eye
`Res. 2014 May;122:77-85. doi: 10.1016/j.exer.2014.03.004. Epub 2014 Mar 22. PubMed
`PMID: 24667088.
`
`Cruz NM, Yuan Y, Leehy BD, Baid R, Kompella U, DeAngelis MM, Escher P, Haider
`NB. Modifier genes as therapeutics: the nuclear hormone receptor Rev Erb alpha (Nr1d1)
`rescues Nr2e3 associated retinal disease. PLoS One. 2014 Jan 31;9(1):e87942. doi:
`10.1371/journal.pone.0087942. eCollection 2014. PubMed PMID: 24498227; PubMed
`Central PMCID: PMC3909326.
`
`Kim SJ, Toma H, Shah R, Kompella UB, Vooturi SK, Sheng J. The safety,
`pharmacokinetics, and efficacy of intraocular celecoxib. Invest Ophthalmol Vis Sci. 2014
`Mar 10;55(3):1409-18. doi: 10.1167/iovs.13-13667. PubMed PMID: 24458149; PubMed
`Central PMCID: PMC3954004.
`
`Yandrapu, S.K., Upadhyay, A.K., Petrash, J.M., and Kompella, U.B.* Nanoparticles in
`porous microparticles (NPinPMP) prepared by supercritical infusion and pressure quench
`technology for sustained delivery of bevacizumab. Mol Pharm. 10(12): 4676-4686 (2013).
`PMID: 24131101.
`
`Rao, V.R., Upadhyay, A.K., Kompella, U.B.* pH shift assembly of adenoviral serotype 5
`capsid protein nanosystems for enhanced delivery of nanoparticles, proteins and nucleic
`acids. J Control Release. 172(1):341-350 (2013). doi: 10.1016/j.jconrel.2013.08.023.
`Epub 2013 Sep 1. PubMed PMID: 24004886.
`
`Chowdhury, S., Guha, R., Trivedi, R., Kompella, U.B., Konar, A., Hazra, S. Pirfenidone
`nanoparticles improve corneal wound healing and prevent scarring following alkali burn.
`PLoS One. 8(8):e70528 (2013). doi: 10.1371/journal.pone.0070528. PubMed PMID:
`23940587; PubMed Central PMCID: PMC3734236.
`
`Tari, S.R., Youssif, M., Samson, C.M., Harris, R.L., Lin, C.M., and Kompella, U.B.,
`Antonetti, D.A., Barile, G.R. Polychromatic angiography for the assessment of VEGF-
`induced BRB dysfunction in the rabbit retina. Invest Ophthalmol Vis Sci. 54(8):5550-5558
`(2013). doi: 10.1167/iovs.13-12144. PubMed PMID: 23882687.
`
`Tyagi, P., Barros, M., Stansbury, J.W., and Kompella, U.B.* Light activated, in situ
`forming gel for sustained suprachoroidal delivery of bevacizumab. Mol Pharm. 10(8):
`2858-2867 (2013) PubMed PMID: 23734705.
`
`12
`
`1.
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`9.
`
`10.
`
`11.
`
`
`
`Metrics EX1052, Page 13
`
`

`
`
`Dhanda, D.S., Tyagi, P., Mirvish, S.S., and Kompella, U.B.* Supercritical fluid
`technology based large porous celecoxib-PLGA microparticles do not induce pulmonary
`dibrosis and sustain drug delivery and efficacy for several weeks following a single dose.
`J Control Release. 168(3):239-250 (2013). PMID: 23562638.
`
`Kompella, U.B.*, Amrite, A.C., Pacha-Ravi, R., Durazo, S.A. Nanomedicines for back of
`the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res. 36:172-198
`(2013). PMID: 23603534.
`
`Bargagna-Mohan, P., Deokule, S.P., Thompson, K., Wizeman, J., Srinivasan, C., Vooturi,
`S., Kompella, U.B., and Mohan, R. Withaferin A effectively targets soluble vimentin in
`the glaucoma filtration surgical model of fibrosis. PLoS One. 8(5):e63881 (2013). doi:
`10.1371/journal.pone.0063881. PMID: 23667686; PMCID: PMC3648549.
`
`Baid, R., Upadhyay, A., Shinohara, T., and Kompella, U.B.* Lens epithelium-derived
`growth
`factor
`therapeutic protein: Biosynthesis,
`fragment (LEDGF1-326), a novel
`characterization, and efficacy in retinal degenerative diseases. J Biol Chem. 288(24):
`17372-17383 (2013). PMID: 23640891; PMCID: PMC3682538.
`
`Sreekumar, P.G., Chothe, P., Sharma, K.K., Baid, R., Kompella, U.B., Spee, C.,
`Kannan, N., Ryan, S.J., Ganapathy, V., Kannan, R., and Hinton, D.R. Antiapoptotic
`properties of α-crystallin-derived peptide chaperones and characterization of their uptake
`transporters in RPE cells. . Invest Ophthalmol Vis Sci. 54(4): 2787-2798 (2013). PMID:
`23532520; PMCID: PMC3632268.
`
`Luo, L., Hirano, Y., Tyagi, P., Barabas, P., Zhang, X., Uehara, H., Miya, T.R., Singh, N.,
`Archer, B., Qazi, Y., Jackman, K., Zygmunt, K., Olsen, T., Ambati, J., Chennamaneni, R.,
`Stagg, B.C., Ahmed, F., Srinivas, S.P., Gao. G., Whitaker, R., Baffi, J., Emerson, L.,
`Krizaj, D., Mamalis, C., Das. S., Huang, W., Kompella, U.B., and Ambati, B.K.
`Functionalized Flt23k
`intraceptor plasmids
`treat murine and primate choroidal
`neovascularizations and improve visual acuity in a murine model. ACS Nano. 7(4): 3264-
`3275 (2013). PMID: 23464925; PMCID: PMC3634882.
`
`Yan